Evaluation of Progressive Retinal Degeneration in Bipolar Disorder Patients over a Period of 5 Years

Abstract

Purpose

To quantify visual and retinal changes in patients with bipolar disorder (BD) over 5 years, compared with controls.

Methods

Thirty-eight patients with BD and 122 healthy subjects underwent visual acuity (VA) evaluation, contrast sensitivity vision testing (CSV) with the Pelli Robson and CSV 1000E tests, and retinal thicknesses measurement [ganglion cell layer (GCL) and retinal nerve fiber layer (RNFL)] using Spectralis Optical Coherence Tomography (OCT). All subjects were re-evaluated after 5 years. The relationship between progressive structural changes and disease duration was analyzed.

Results

Visual function parameters in BD patients remained unchanged during the follow-up period. A progressive decrease affecting macular and peripapillary RNFL thickness (p < 0.050) was observed in patients. Progressive changes in BD were more pronounced when compared with healthy controls (p < 0.050). A significant correlation between GCL thickness changes and disease duration was found (GCL outer temporal, r = −0.680, p = 0.016; GCL central, r = −0.540, p = 0.038).

Conclusions

Progressive axonal loss was detected in BD patients. Visual function parameters were not affected after the 5-year follow-up. Despite observed changes in the neuroretina of patients with BD, axonal degeneration in these patients seemed to be mild and might be slowed down by other factors, such as BD treatments.

Keywords:

• Bipolar disorder
• progressive retinal degeneration
• ganglion cell layer
• retinal nerve fiber layer

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Additional information

Funding

This study received no specific funding. This work was supported by Instituto de Salud Carlos III (PI17/01726 and PI17/01946) and by MINECO/AEI/FEDER, UE (MAT2017-83858-C2-2). MS was supported by the Juan Rodes program (JR2017/00010) by Instituto de Salud Carlos III.